{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:26:15Z","timestamp":1790724375758,"version":"4.1.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.03123","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T04:34:47Z","timestamp":1579840487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":110,"title":["High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Stephan","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bexte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Gebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Kalensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Stolzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Koehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried S.","family":"Wels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Modlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"B1","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.1997.tb00978.x","article-title":"Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy","volume":"157","author":"Goulmy","year":"1997","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ni1580","article-title":"Natural killer cell-directed therapies: moving from unexpected results to successful strategies","volume":"9","author":"Terme","year":"2008","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e26097","DOI":"10.4161\/onci.26097","article-title":"New prospects on the NKG2D\/NKG2DL system for oncology","volume":"2","author":"Ullrich","year":"2013","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1600-065X.2006.00460.x","article-title":"Activation and self-tolerance of natural killer cells","volume":"214","author":"Gasser","year":"2006","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the missing self: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00262-004-0517-9","article-title":"The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape","volume":"53","author":"Algarra","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"B28","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","article-title":"Utilizing chimeric antigen receptors to direct natural killer cell activity","volume":"6","author":"Hermanson","year":"2015","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J Hematother Stem Cell Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000495771","article-title":"CAR-expressing natural killer cells for cancer retargeting","volume":"46","author":"Kloess","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4054815","DOI":"10.1155\/2018\/4054815","article-title":"Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies","volume":"2018","author":"Matosevic","year":"2018","journal-title":"J Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2017.00458","article-title":"Shaping of natural killer cell antitumor activity by ex vivo cultivation","volume":"8","author":"Granzin","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jim.2017.08.003","article-title":"Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21","volume":"450","author":"Streltsova","year":"2017","journal-title":"J Immunol Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","article-title":"Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens","volume":"53","author":"Boissel","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymthe.2005.08.012","article-title":"Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells","volume":"13","author":"Schambach","year":"2006","journal-title":"Mol Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1128\/JVI.00182-10","article-title":"Self-inactivating alpharetroviral vectors with a split-packaging design","volume":"84","author":"Suerth","year":"2010","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/ijc.30217","article-title":"Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival","volume":"139","author":"Oelsner","year":"2016","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e9158","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2001-11-0042","article-title":"Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates","volume":"100","author":"Sandrin","year":"2002","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J Mol Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1073\/pnas.96.5.2129","article-title":"The RD114\/simian type D retrovirus receptor is a neutral amino acid transporter","volume":"96","author":"Rasko","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1038\/mtna.2013.17","article-title":"Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells","volume":"2","author":"Fenard","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1096\/fj.05-4293fje","article-title":"The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes","volume":"20","author":"Mason","year":"2006","journal-title":"FASEB J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1074\/jbc.M115.675033","article-title":"Molecular determinants of vectofusin-1 and its derivatives for the enhancement of lentivirally mediated gene transfer into hematopoietic stem\/progenitor cells","volume":"291","author":"Majdoul","year":"2016","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.omtm.2017.02.003","article-title":"Vectofusin-1 promotes RD114-TR-pseudotyped lentiviral vector transduction of human HSPCs and T lymphocytes","volume":"5","author":"Piovan","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nm0896-876","article-title":"Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells","volume":"2","author":"Hanenberg","year":"1996","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.actbio.2017.10.009","article-title":"Vectofusin-1, a potent peptidic enhancer of viral gene transfer forms pH-dependent \u03b1-helical nanofibrils, concentrating viral particles","volume":"64","author":"Vermeer","year":"2017","journal-title":"Acta Biomater"},{"key":"B53","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Kl\u00f6\u00df","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/hgtb.2019.039","article-title":"Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering","volume":"30","author":"Oberschmidt","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/mt.2011.309","article-title":"Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity","volume":"20","author":"Suerth","year":"2012","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/mt.2012.249","article-title":"Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing","volume":"21","author":"Kaufmann","year":"2013","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3389\/fimmu.2019.02001","article-title":"A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy","volume":"10","author":"Bari","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","article-title":"Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs","volume":"124","author":"Girard-Gagnepain","year":"2014","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.1128\/JVI.74.17.8085-8093.2000","article-title":"Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus","volume":"74","author":"Marin","year":"2000","journal-title":"J Virol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.153.3.615","article-title":"Recycling and target binding capacity of human natural killer cells","volume":"153","author":"Ullberg","year":"1981","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1371\/journal.pone.0000326","article-title":"Serial killing of tumor cells by human natural killer cells\u2013enhancement by therapeutic antibodies","volume":"2","author":"Bhat","year":"2007","journal-title":"PLoS ONE"},{"key":"B63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2141.2010.08297.x","article-title":"Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-hodgkin lymphoma","volume":"151","author":"Mihara","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T04:34:50Z","timestamp":1579840490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.03123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2019.03123"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.03123","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"article-number":"3123"}}